DMAA
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQFINANCIAL SERVICESSHELL COMPANIES
Key Statistics
Market Cap
$355.55M
P/E Ratio
55.50
EPS
$0.19
Beta
—
52W High
$10.56
52W Low
$10.05
50-Day MA
$10.49
200-Day MA
$10.36
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company focused on transforming the U.S. pharmaceutical industry through strategic partnerships with innovative firms dedicated to enhancing domestic drug production and distribution. In response to growing concerns over supply chain vulnerabilities, DMAA aims to facilitate the development of more accessible and cost-effective pharmaceuticals, thereby addressing critical market needs. By investing in technological advancements and fostering collaboration within the healthcare sector, DMAA is positioned to play a pivotal role in revitalizing local manufacturing and improving consumer access to essential medications.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.21 |
| Price-to-Book | 1.53 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.72M |
| Float | $27.31M |
| % Insiders | 26.61% |
| % Institutions | 70.05% |
Historical Volatility
HV 10-Day
1.38%
HV 20-Day
1.63%
HV 30-Day
2.68%
HV 60-Day
2.32%
HV Rank
77.8%
Volatility is currently contracting
Data last updated: 4/25/2026